Hysteroscopic anesthesia
Conditions
Interventions
Propofol combined with 0.2mg/kg esketamine (Group A):Esketamine was administered intravenously at a dose of 0.2mg/kg, and propofol was administered 30 seconds after injection. The initial dose of prop
Propofol combined with 0.35mg/kg esketamine (Group B):Esketamine was administered intravenously at a dose of 0.35mg/kg, and propofol was administered 30 seconds after injection. The initial dose of pr
Propofol combined with 0.5mg/kg esketamine (Group C):Esketamine was administered intravenously at a dose of 0.5mg/kg, and propofol was administered 30 seconds after injection. The initial dose of prop
Sponsors
People's Hospital of Ningxia Hui Autonomous Region
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) Age 20-50 years old; (2) BMI 18.5 ~ 25 kg/m2; (3) ASA ? or ? level; (4) Painless hysteroscopy was performed; (5) Agree to participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Preoperative history of hypertension, hyperthyroidism, neurological and psychiatric diseases; (2) had taken or was recently taking opioids and non-steroidal anti-inflammatory drugs 48 hours before surgery, and (3) had participated in clinical trials of other drugs within the last 4 weeks; (4) Allergic to the investigational drug esketamine or propofol; (5) A history of addiction to opioids and esketamine. (6) Other circumstances not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90% effective dose of propofol; | — |
Secondary
| Measure | Time frame |
|---|---|
| Response of each group of patients during hysteroscopy examination;The frequency of patient movements during hysteroscopy examination;The time from administration to MOAA/S score<2 points and from discontinuation to MOAA/S score = 4 points;Pain level of the patient at 5, 15, and 30 minutes after awakening (based on VAS score);The incidence of cardiovascular complications and other perioperative adverse events; | — |
Countries
China
Contacts
Public ContactWang Yun
People's Hospital of Ningxia Hui Autonomous Region
Outcome results
None listed